Ipamorelin is a synthetic peptide that nudges the pituitary to release growth hormone. It was trialled by pharma for post-operative ileus, failed to win approval and was dropped. Today it is sold only as a research chemical and used off-label in wellness clinics — and it is banned at all times in tested sport by WADA.
CJC-1295 is a synthetic copy of growth hormone–releasing hormone (GHRH), engineered to last in the body for days rather than minutes. It was tested in early human trials in the mid-2000s, abandoned by its developer, and now circulates only as a research chemical. It is not an approved medicine anywhere, and is banned at all times in tested sport by WADA.
Ipamorelin sits at grade C; CJC-1295 at grade D. On evidence alone, Ipamorelin is the safer recommendation. That said, "stronger evidence" doesn't always mean "right for you" — read both pages, then talk to a clinician.
The one indication ipamorelin reached human trials for. A randomised, placebo-controlled phase 2 study in bowel-resection patients (Beck et al. 2014) reported some signal on gastric motility but missed its primary endpoint. Development was halted.
Reliably raises GH in animals and healthy volunteers in short-duration studies. Whether sustained micro-pulses translate to meaningful long-term clinical outcomes in humans is not established.
The Teichman 2006 Phase I trial established that a single dose raises GH and IGF-1 for several days. This is a pharmacokinetic finding, not a clinical outcome — no approved indication followed.
ConjuChem ran a Phase II trial for fat-redistribution in HIV-positive patients. The trial was halted in 2006 after a patient death; development of CJC-1295 was effectively abandoned soon after.
Widely used off-label in bodybuilding circles, often stacked with ipamorelin or other GH secretagogues. No controlled human trial has tested body-composition endpoints.
In short-duration human trials ipamorelin was generally well tolerated, with the most common reports being injection-site reactions, mild headache and transient flushing. Longer-term safety in healthy adults using it for performance or anti-ageing reasons is unknown — there are no multi-month controlled trials in this population. Chronic stimulation of the GH/IGF-1 axis is the main theoretical concern: it could in principle worsen insulin resistance, drive water retention, accelerate diabetic retinopathy, or promote the growth of pre-existing tumours (IGF-1 is mitogenic). People with active cancer, a cancer history, diabetes, or who are pregnant or breastfeeding should not use it. Products sold as "ipamorelin" online are unregulated research chemicals — purity, sterility and dose-per-vial vary, and contamination is a real risk.
The safety profile in humans is essentially unknown. The Teichman Phase I trial reported headache, flushing, and injection-site reactions as the commonest dose-related adverse events. The class as a whole — GH secretagogues — is associated with reduced insulin sensitivity, raised blood glucose, and fluid retention at doses that meaningfully raise IGF-1, all of which are concerns for long-term, unsupervised use. There is also a well-recognised theoretical risk that sustained IGF-1 elevation could promote the growth of existing tumours; this has not been demonstrated for CJC-1295 specifically but is a standard caution across the GH/IGF-1 axis.
A single trial-participant death occurred during the 2006 ConjuChem lipodystrophy Phase II study; the attending physician's judgement was that the death (asymptomatic coronary disease with plaque rupture) was most likely unrelated to CJC-1295, but the study was halted and the programme was effectively abandoned shortly after. Online lore that has grown around this — including reports of unexplained deaths in users in subsequent years — is poorly documented and causation has not been established. We mention it because it is part of the public record, not because the link is proven.
Ipamorelin sits at grade C; CJC-1295 at grade D. On evidence alone, Ipamorelin is the safer recommendation. That said, "stronger evidence" doesn't always mean "right for you" — read both pages, then talk to a clinician.
Pepwyse comparison pages are generated from the same structured data behind each peptide profile. Want a different head-to-head? Use the compare picker or ask Ipamorelin directly via the Ask-Peppy button. Not medical advice — see how we grade evidence.